STOCK TITAN
  1. Home
  2. News
  3. IDYA

Ideaya Biosciences Inc - IDYA STOCK NEWS

Welcome to our dedicated news page for Ideaya Biosciences (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ideaya Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ideaya Biosciences's position in the market.

News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) granted 40,000 non-qualified stock options to a newly hired employee under the 2023 Employment Inducement Incentive Award Plan. The options have an exercise price of $31.45 per share, a 10-year term, and will vest over four years. Vesting is subject to the employee's continued service to IDEAYA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
News
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
Rhea-AI Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) to participate in Barclays Lunchtime Fireside Chat Series with CEO Yujiro S. Hata and Equity Research Analyst Peter Lawson on December 5th, 2023 at 12:00 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
conferences
-
News
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
Rhea-AI Summary
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has entered into a clinical study collaboration and supply agreement with Gilead Sciences, Inc. to evaluate IDE397, a potential first-in-class MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ('Trodelvy'), Gilead's Trop-2 directed ADC, in MTAP-deletion bladder cancer. The prevalence of MTAP-deletion in bladder cancer is estimated to be approximately 26%. IDEAYA will sponsor the clinical trial, and Gilead will provide Trodelvy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
clinical trial
News
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
Rhea-AI Summary
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announces agenda topics for its Investor R&D Day, showcasing scientific insights and clinical development opportunities across its synthetic lethality pipeline, including Phase 2 and Phase 1 programs. The webcast event will be hosted on Monday, December 4, 2023, featuring presentations by IDEAYA management and key opinion leaders. Registration is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
IDEAYA Biosciences, Inc. provided a business update and announced financial results for the third quarter ended September 30, 2023. The company reported a strong balance sheet with $511.1 million in cash, cash equivalents, and marketable securities, supplemented by $134.7 million in net proceeds from follow-on financing. Multiple patients were dosed, and international site activation and enrollment are ongoing in Phase 2/3 trials for darovasertib and crizotinib combination in uveal melanoma. The company also reported positive clinical data for various treatments and achieved IND clearance for GSK101, triggering milestone payments of $7.0 million and $3.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
earnings
-
News
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference
Rhea-AI Summary
IDEAYA Biosciences, a precision medicine oncology company, will participate in the Jefferies London Healthcare Conference and host an Investor R&D Day. The Investor R&D Day will feature GSK and a key opinion leader discussing IDEAYA's synthetic lethality pipeline. IDEAYA will also highlight its MTAP-deletion initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
none
News
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Rhea-AI Summary
IDEAYA Biosciences closes underwritten public offering, raising approximately $143.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
IDEAYA Biosciences grants non-qualified stock options to a newly hired employee. The options have an exercise price of $27.06 per share and a 10-year term. They will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.51%
Tags
none
-
News
IDEAYA Announces Pricing of Public Offering
Rhea-AI Summary
IDEAYA Biosciences, Inc. announces pricing of public offering of common stock and pre-funded warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
offering
News
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
IDEAYA Biosciences announces plans for a public offering of up to $125.0 million of its common stock and pre-funded warrants. The offering is subject to market conditions and the underwriters have a 30-day option to purchase additional shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
offering
Stock IDYA logo
Ideaya Biosciences Inc

Nasdaq:IDYA

IDYA Rankings

#1597 Ranked by Market Cap
#381 Ranked by Stock Gains
N/A Ranked by Dividends

IDYA Stock Data

3.13B
73.78M
0.98%
102.9%
12.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.